75%Confidence
0Views
FDASource
2026-03-14Date
Summary
Slate Run Pharmaceuticals recalls Eptifibatide Injection due to labeling error on dosing instructions, a Class III issue indicating lower health risk but potential for medication errors. This highlights regulatory compliance challenges in packaging and may affect hospital trust in the product.
Actionable: Verify labeling accuracy for cardiovascular drugs in inventory and confirm dosing protocols with healthcare providers.
AI Confidence: 75%
Data Points
firmSlate Run Pharmaceuticals
classificationClass III
statusOngoing
distributionNationwide within the USA.
productEptifibatide Injection, 75 mg/100 mL vial for weight-adjusted bolus dosing, 1x100 mL Single-dose Vial, For Intravenous Use Only, Rx Only, Manufactured
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now